Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selec...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Flaherty, Keith T., Infante, Jeffery R., Daud, Adil, Gonzalez, Rene, Kefford, Richard F., Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A., Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V., Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B., Patel, Kiran, Weber, Jeffrey
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549295/
https://ncbi.nlm.nih.gov/pubmed/23020132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1210093
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker